Thursday, Sep 24, 2020 | Last Update : 04:59 AM IST

183rd Day Of Lockdown

Maharashtra122438091634833015 Andhra Pradesh6317495518215410 Tamil Nadu5473374919718871 Karnataka5268764233778145 Uttar Pradesh3588932895945135 Delhi2492592133045014 West Bengal2283021989834421 Odisha184122149379763 Telangana1726081419301042 Bihar169856155824870 Assam159320129130578 Kerala13863398720554 Gujarat1247671051913337 Rajasthan116881972841352 Haryana113075908841177 Madhya Pradesh108167836182007 Punjab99930754092860 Chhatisgarh8618347653680 Jharkhand7267358543626 Jammu and Kashmir65026421151024 Uttarakhand4177729000501 Goa2875322726360 Puducherry2319118065467 Tripura2227215441245 Himachal Pradesh124387836125 Chandigarh102987411123 Manipur9010683859 Arunachal Pradesh7385540813 Nagaland5544445110 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  World   Americas  06 May 2020  Trump administration ignored COVID-19 warnings, alleges fired American scientist

Trump administration ignored COVID-19 warnings, alleges fired American scientist

Published : May 6, 2020, 9:35 am IST
Updated : May 6, 2020, 9:35 am IST

Scientist in US turns whistleblower against government's decision to flood its market with malaria drug without proper inspection

US President Donald Trump. (AFP)
 US President Donald Trump. (AFP)

Washington: Top health officials of the Trump administration repeatedly ignored multiple warnings with regard to the coronavirus pandemic, including the alleged poor quality of malaria drug hydroxychloroquine from India and Pakistan, a fired American scientist has said in a whistleblower complaint.

In a complaint filed on Tuesday before the US Office of Special Counsel, which oversees protection of whistleblowers, Rick Bright alleged that top officials of the Department of Health and Human Services repeatedly ignored his messages and that of others with regard to personal protective equipment and medicines like hydroxychloroquine in particular.


When fired, Bright was head of the Biomedical Advanced Research and Development Authority, a research agency within the Health and Human Services (HHS) Department. He reported directly to Robert Kadlec, the assistant secretary of preparedness and response at the US Department of Health and Human Services.

"Dr Bright remained extremely concerned about the drug's importation from Pakistan and India because the FDA had not inspected the drugs or the factory that produced them," the complaint said.

"In Dr Bright's experience, drugs from uninspected factories can be contaminated or dosed improperly, and this could obviously be dangerous to those who took the medication. Apparently unconcerned about this known danger, Dr Kadlec and others in the administration sought to 'flood' the marketplace with these drugs," it alleged.


The Trump administration has imported nearly five crore units of the malaria drug, hydroxychloroquine, which in March had received Emergency Use Authorisation from the US Food and Drug Administration (FDA).

The Trump administration, the complaint said, was not interested in hearing from Bright and his department or subject matter experts.

"Dr Bright and his team had apparently spent all their political capital in their effort to limit chloroquine and rushing into a potentially dangerous situation and that there was no one to help stop the push to 'flood' the country with this unproven and potentially dangerous drug," the complaint said.


"He concluded that his only remaining avenue was to share his concerns with the journalist who understood the specific issue and risks associated with these drugs and who had already gathered substantial information from multiple sources," it added.

The complaint alleged that HHS Secretary Alex Azar's directive to secure a Nationwide Expanded Access IND protocol for chloroquine, based on scant scientific evidence and on such a short time-frame, sent Bright and his colleagues scrambling.

Within the hour, Bright had called a meeting of Dr Linda Lambert, Chief Medical Officer Dr Robert Walker, Director of Regulatory and Quality Affairs Dr Tremel Faison, and Drs Johnson, Disbrow and Houchens to discuss the directive.


The group expressed serious concerns about a Nationwide Expanded Access IND protocol for chloroquine given the lack of clinical data available about its therapeutic benefits and concerns about its potential safety risks, especially if administered without close physician supervision, it said.

Bright and his FDA colleagues were also concerned about the quality and potential toxicity of the chloroquine supplies produced and shipped in from facilities in India and Pakistan that were not approved by the FDA and therefore, not approved to be used in the US marketplace.

The HHS clinical and regulatory expert teams worked frantically for 48 hours without sleep to come up with a plan that would ensure the greatest level of safety for people who received this drug.


They discussed narrower options for the rollout, including a small pilot study, and established an inter-agency working group of clinical and regulatory experts to determine the safest way to make the unproven drug available without causing harm to the American public, the complaint said.

When fired earlier, Bright alleged that he was ousted because of his "insistence" that the government spend funds on "safe and scientifically-vetted solutions" to address the coronavirus crisis and not on "drugs, vaccines and other technologies that lack scientific merit".

Tags: rick bright, scientist, coronavirus, covid-19, hydroxychloroquine, malaria drug, warnings, india, pakistan
Location: United States, Washington, Seattle